Loading
RPG Life Sciences Limited Stock: price and insider trades · India
No insider purchase over the last 90 days. The latest, by Nucleus Life Trust, was filed 26 Dec 2024.
Insider Decl.
51
Thresholds
n/a
Buy Volume
€1M
51 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleNucleus Life Trust24 buys
Since the insiders bought
- +9.7%Entry ₹2,119.60 · Close at T+365 ₹2,325.40
- +59.2%Entry ₹570.00 · Close at T+365 ₹907.25
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 9,118 of 26,280 companies
59.1
score / 100
Value33
Quality86
FCF yld-0.2%
Earn yld2.4%
EV/EBITDA26.7x
ROE20%
Gross mgn63%
Net mgn16%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended March 2026 · cache
₹2,843.00
Analyst consensus
1 analysts₹3,205.00Target ₹3,205.00(+13%)₹3,205.00
Income statement
Revenue₹7B
Gross profit₹4.4B63% margin
EBITDA₹1.8B25% margin
Net income₹1.2B16.3% margin
Valuation
PER (trailing)39.3x
PER (forward)30.2x
P/Book7.8x
Beta-0.13
Balance sheet & cash
Market cap₹47B
Total debt₹200M
Free Cash Flow-₹88.6M
Debt / Equity3%
Profitability & ownership
ROE20.3%
ROA10.8%
% insiders76.5%
% institutions5.6%
Last declaration on 26 December 2024
Declarations51 total
1,800 shares@ ₹2,187.36113.9% of flowEquity SharesSEBI:a3ee00ed96780c34c966b7cf41a01e4623583067
Canonical exit: 24 Mar 2025 (T+90)
10 shares@ ₹2,170.000.0% of flowEquity SharesSEBI:68052c5e66854b6655ab31e8bd8f788e144f4e10
Canonical exit: 23 Mar 2025 (T+90)
10 shares@ ₹2,196.000.0% of flowEquity SharesSEBI:b06002e5febeb33ca5a441f9088462dc0ccdd9a3
Canonical exit: 20 Mar 2025 (T+90)
2,012 shares@ ₹2,195.38124.4% of flowEquity SharesSEBI:68323f92cba7b478332b4899799dc61f1097913d
Canonical exit: 20 Mar 2025 (T+90)
874 shares@ ₹2,174.22081.9% of flowEquity SharesSEBI:b2c6bf82fe718ec56bd17e4de67f5822efbe9abc
Canonical exit: 23 Mar 2025 (T+90)
500 shares@ ₹2,233.001.1% of flowEquity SharesSEBI:7d1d11e4f3a11b6a7f8c4d3049702b22a01d944a
Canonical exit: 18 Mar 2025 (T+90)
249 shares@ ₹2,197.20880.6% of flowEquity SharesSEBI:df2ead7b455253b67b1f46bc5240c4936ffc5054
Canonical exit: 19 Mar 2025 (T+90)
330 shares@ ₹2,254.05150.7% of flowEquity SharesSEBI:45a83e91010464517d99f442ba516dac33672550
Canonical exit: 17 Mar 2025 (T+90)
200 shares@ ₹2,270.050.4% of flowEquity SharesSEBI:e19fd57c81b1a83c6c35882dd843903f2ca42afa
Canonical exit: 16 Mar 2025 (T+90)
720 shares@ ₹2,253.72361.6% of flowEquity SharesSEBI:7c1f450758234fbd4a16881e6e2e6eec252a3048
Canonical exit: 13 Mar 2025 (T+90)
235 shares@ ₹2,280.71910.5% of flowEquity SharesSEBI:cbb76f54d9a895330800e072085f62db5bc508bc
Canonical exit: 12 Mar 2025 (T+90)
2,941 shares@ ₹2,258.73386.6% of flowEquity SharesSEBI:f2ca79dd9c8e0b13938576b81da8d245559f49d8
Canonical exit: 13 Mar 2025 (T+90)
10 shares@ ₹2,190.000.0% of flowEquity SharesSEBI:6198117355712e0a78531108d38cd14f61988010
Canonical exit: 6 Mar 2025 (T+90)
793 shares@ ₹2,174.72511.7% of flowEquity SharesSEBI:1cd3911d768eff52124ec13083c1b4596ddc8b99
Canonical exit: 5 Mar 2025 (T+90)
37 shares@ ₹2,187.89190.1% of flowEquity SharesSEBI:4ad706cc858e046dd41438bd2d3898729296efe3
Canonical exit: 6 Mar 2025 (T+90)
34 shares@ ₹2,170.88240.1% of flowEquity SharesSEBI:fe7746d53a55db1a1f0a153225c94f7494902d89
Canonical exit: 5 Mar 2025 (T+90)
10 shares@ ₹2,200.000.0% of flowEquity SharesSEBI:693813b7dec2a8fb53b61206319548a9f0a41d57
Canonical exit: 3 Mar 2025 (T+90)
25 shares@ ₹2,197.000.1% of flowEquity SharesSEBI:f5da17ecd1dc74b7415e255aebfa8a14d4483ff8
Canonical exit: 2 Mar 2025 (T+90)
5 shares@ ₹2,200.000.0% of flowEquity SharesSEBI:48c7da21e7fc085d8a94af7ca5bcd6ef8fe2a1f1
Canonical exit: 2 Mar 2025 (T+90)
2,595 shares@ ₹2,200.40155.7% of flowEquity SharesSEBI:bb8fe693f05b7a7ab77b18e7e1f7bbe181dd6a64
Canonical exit: 3 Mar 2025 (T+90)
1,859 shares@ ₹2,100.19693.9% of flowEquity SharesSEBI:51bbe5fd48911fe8ce283d3ec5c272f9273a6762
Canonical exit: 26 Feb 2025 (T+90)
4,412 shares@ ₹2,207.19499.7% of flowEquity SharesSEBI:0081a5250a5cb7a6bb86cac41f2a51d024a3d347
Canonical exit: 27 Feb 2025 (T+90)
3,048 shares@ ₹2,187.95246.6% of flowEquity SharesSEBI:df6d818c156e7d7fbd2dd6894776431977f150ee
Canonical exit: 27 Feb 2025 (T+90)
306 shares@ ₹2,085.72550.6% of flowEquity SharesSEBI:a272673642a5e269a4262a908732b381b7fc1ad3
Canonical exit: 26 Feb 2025 (T+90)
19,360 shares@ ₹858.51616.6% of flowEquity SharesSEBI:f2522bc748902426b599afc84c47b45a9bad8b33
Canonical exit: 10 May 2023 (T+90)
25 of 51 declarations
About RPG Life Sciences Limited
The record of RPG Life Sciences Limited (health care, Bombay Stock Exchange) is entirely on the buying side: 51 filings, 51 purchases, no sale and no grant. Two entities share everything: Nucleus Life Trust with 31 filings and Ektara Enterprises LLP with 20. Purchases total EUR 1,469,137, with a median of EUR 12,427.
The three largest all come from Nucleus Life Trust: EUR 187,467 on February 9, 2023, EUR 178,962 on August 10, 2022 and EUR 109,057 on November 29, 2024. The 51 filings run from May 30, 2022 to December 26, 2024, with 22 in 2022, 5 in 2023 and 24 in 2024. None was published in the last twelve months.
Read moreShow less
The two filers hold 76.5% of a company worth INR 47.0 billion. Filings appear a median of 3 days after the trade. For all 51 purchases a 90-day result is stored: a median of 5.3%, 61% of results positive, recorded past results and not a forecast.
